Search
Fulcrum Therapeutics Inc
FULCAdd to Watchlist
3.770USD
+0.090+2.45%
Close 11-13 16:00（ET）
287.65MMarket Cap
LossP/E TTM
Fulcrum Therapeutics Inc (FULC) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Fulcrum Therapeutics Inc in the past month.
Hold
0 Strong Buy
0 Buy
4 Hold
1 Sell
0 Strong Sell
Target Price
7.600USD+104.85%
FULC Analyst Recommendation Trends
In the current month, FULC has received 0 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. FULC average Analyst price target in the last month is 7.600.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
3
3
3
3
0
0
0
0
5
5
5
5
4
4
5
5
1
1
1
1
0
0
0
0
0
0
0
0
1
1
2
3
1
1
1
1
5
5
7
8
10
10
10
10
FULC Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, FULC EPS is projected to reach -0.102 in FY2026Q4, following reported EPS of -0.143 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.30
-0.22
-0.11
-0.10
-0.36
Actual
-0.25
-0.34
-0.14
--
--
Surprise
+16.88%
-56.03%
-35.23%
--
--
FAQs
What is Fulcrum Therapeutics Inc's price target?
Analysts forecast that Fulcrum Therapeutics Inc's price target is USD 7.60, with the highest forecast at USD 24.00 and the lowest forecast at USD 3.00.
How have Fulcrum Therapeutics IncFULC's recent earnings per share performed?
The market expectation was USD -0.14, while Fulcrum Therapeutics IncFULC's earnings per share (EPS) for the previous quarter was USD -0.34. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for Fulcrum Therapeutics Inc?
Based on the ratings of Fulcrum Therapeutics Inc's stock from 5 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.